Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non–Small-Cell Lung Cancer: COMPASS (WJOG5610L) In the PETHEMA/GEM2012MENOS65 ...
New tools for monitoring multiple myeloma were a key topic at the European Hematology Society Congress. Advances in drugs and combinations have revolutionized the landscape in multiple myeloma, thus ...
Minimal residual disease (MRD) has emerged as a significant marker in the treatment of multiple myeloma (MM), allowing clinicians to make more informed decisions about therapy. MRD testing helps gauge ...
Please could you both introduce yourselves and give a brief outline of your roles at Cerba Research? ADB: My name is Ans De Beuckelaer. I have a Ph.D. in biotechnology from the University of Ghent. In ...
At ASH 2025, investigators reported early results from the first-in-human phase 1 inMMyCAR study evaluating KLN-1010, an ...
In part 2 of our interview with Surbhi Sidana, MD, MBBS, American Society of Hematology and Stanford University, she delves into one of the hottest topics in the hematologic malignancy space today: ...
Researchers at the Cima University of Navarra (Spain), in collaboration with the Spanish Myeloma Group (GEM-PETHEMA), have developed a calculator that identifies patients with multiple myeloma and ...
Around the same time, Mack Fulwyler, an engineer working at Los Alamos National Laboratory, needed to separate particles, so he drew on existing techniques to create droplets to separate cells from a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback